Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials

AIDS

Volumn 15, Issue 12, 2001, Pages 1584-1586

  Coplan, P M ^a   Nikas, A A ^a   Leavitt, R Y ^a   Doll, L ^a   Nessly, M L ^a   DiNubile, M J ^a   Guess, H A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANGINA PECTORIS; ANTIMICROBIAL THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MORTALITY; PERIPHERAL VASCULAR DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RISK FACTOR; STROKE; VIRUS LOAD;

ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE III; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; INDINAVIR; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 0035902914     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200108170-00020     Document Type: Article

References (16)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Deaths: Final data for 1997
3. Changing patterns of mortality across Europe in patients infected with HIV-1
4. HIV and AIDS in the Asia-Pacific region: An epidemiological overview
5. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
6. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
7. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
8. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy
9. Severe premature coronary heart disease with protease inhibitors
10. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors
11. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors
12. Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients?
13. Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment?
14. The use of pharmacoepidemiology to study beneficial drug effects
15. Comparative analysis of two rates
16. Epidemiologic programs for computers and calculators. Exact binomial confidence intervals for the relative risk in follow-up studies with sparsely stratified incidence density data